{"id":528080,"date":"2021-01-29T13:04:01","date_gmt":"2021-01-29T13:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=528080"},"modified":"2021-01-29T13:04:01","modified_gmt":"2021-01-29T13:04:01","slug":"idiopathic-pulmonary-fibrosis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_528080.html","title":{"rendered":"Idiopathic Pulmonary Fibrosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Idiopathic Pulmonary Fibrosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Idiopathic Pulmonary Fibrosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\"><strong>Idiopathic pulmonary fibrosis (IPF)<\/strong> is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function, that primarily occurs in those 50 years and older. Various causes including genetic susceptibility, environmental risk factors, and exposures have been suggested in the literature. All of these cause repetitive micro-injury to the lung tissue and vasculature, which triggers a cascade of inflammatory response and fibrosis.<\/p>\n<p style=\"text-align: justify;\"><strong>IPF<\/strong> affects approximately 132,000 people in the US with about 50,000 new diagnoses every year. However, as the symptoms of IPF are similar to other lung diseases, like asthma and chronic obstructive lung disease&nbsp;(COPD), this results in misdiagnosis of initial presentation. Diagnosis requires a high index of clinical suspicion supported by distinct radiographic and\/or histopathologic&nbsp;findings. Median survival is estimated at between 2 and 3 years after diagnosis. Other than lung&nbsp;transplantation, no treatment has shown survival benefit.<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<br \/><\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/idiopathic-pulmonary-fibrosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/idiopathic-pulmonary-fibrosis-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">The <strong>Idiopathic Pulmonary Fibrosis market report<\/strong> also covers emerging drugs, current treatment practices, Idiopathic Pulmonary Fibrosis market share of the individual therapies, current and forecasted Idiopathic Pulmonary Fibrosis Market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides a detailed current <strong>Idiopathic Pulmonary Fibrosis treatment practice<\/strong>\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Idiopathic Pulmonary Fibrosis Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/803f48ad658c3167b8b4eb5302340c34.jpg\" alt=\"Idiopathic Pulmonary Fibrosis Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The total <\/span><strong><span data-mce-mark=\"1\">prevalent population of Idiopathic Pulmonary Fibrosis (IPF)<\/span><\/strong><span data-mce-mark=\"1\"> in the 7MM expected to rise during the study period [2017&ndash;2030]. Estimates show the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF) is in the United States followed by the UK.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">According to DelveInsight&rsquo;s analysis, it had been observed that Moderate <strong>Idiopathic Pulmonary Fibrosis (IPF) cases<\/strong> are more prominent in comparison to Mild and Severe cases across 7 MM.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Males have a higher <\/span><strong><span data-mce-mark=\"1\">prevalence of Idiopathic Pulmonary Fibrosis<\/span><\/strong><span data-mce-mark=\"1\"> as compared to females.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Among the European 5 countries, the United Kingdom had the highest<\/span><strong>prevalent population of Idiopathic Pulmonary Fibrosis (IPF)<\/strong><span>, followed by Italy and Germany. On the other hand, Spain had the lowest prevalent population of IPF.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The lowest prevalent <\/span><strong>population of Idiopathic Pulmonary Fibrosis (IPF)<\/strong><span> was recorded in Japan.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Idiopathic Pulmonary Fibrosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis market report<\/strong> provides an in-depth analysis of Idiopathic Pulmonary Fibrosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The<strong> Idiopathic Pulmonary Fibrosis market report<\/strong> will help in developing business strategies by understanding the Idiopathic Pulmonary Fibrosis Market trends &amp; developments, key players and future market competition that will shape and drive the Idiopathic Pulmonary Fibrosis market in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The <strong>Idiopathic Pulmonary Fibrosis market<\/strong> report covers Idiopathic Pulmonary Fibrosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the <strong>Idiopathic Pulmonary Fibrosis market<\/strong> in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population,&nbsp; comparative analysis of pipeline products with detailed clinical profiles, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Idiopathic Pulmonary Fibrosis Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>The Idiopathic Pulmonary Fibrosis market is expected to increase during the forecast period owing to the increasing prevalent population of Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;The <strong>Idiopathic Pulmonary Fibrosis market outlook<\/strong> section of the report helps to build the detailed comprehension of the historic, current and forecasted Idiopathic Pulmonary Fibrosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of <strong>Idiopathic Pulmonary Fibrosis market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Idiopathic Pulmonary Fibrosis Epidemiology<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Idiopathic Pulmonary Fibrosis epidemiology<\/strong> section covers insights about historical and current Idiopathic Pulmonary Fibrosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Drugs Uptake and Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Idiopathic Pulmonary Fibrosis Drugs<\/strong> Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched in the market during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">&nbsp;The available therapeutics treatment options in Idiopathic Pulmonary Fibrosis (IPF) Landscape aims to slow the disease progression and not stop the disease to improve survival benefits. To overcome the drawbacks of the treatment many companies are working robustly to identify the cause of disease and targeted therapy.<\/p>\n<p style=\"text-align: justify;\"><strong>The key companies in the Idiopathic Pulmonary Fibrosis market include:<\/strong><br \/><strong>FibroGen<\/strong><br \/><strong>Kadmon Corporation<\/strong><br \/><strong>Promedior<\/strong><br \/><strong>Galapagos<\/strong><br \/><strong>MediciNova<\/strong><br \/><strong>And others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Idiopathic Pulmonary Fibrosis therapies covered in the report include:<\/strong><br \/><strong>Pamrevlumab<\/strong><br \/><strong>KD025<\/strong><br \/><strong>PRM-151<\/strong><br \/><strong>GLPG1690<\/strong><br \/><strong>Tipelukast<\/strong><br \/><strong>And many more.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Idiopathic Pulmonary Fibrosis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Idiopathic Pulmonary Fibrosis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Idiopathic Pulmonary Fibrosis Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Idiopathic Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Idiopathic Pulmonary Fibrosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Idiopathic Pulmonary Fibrosis Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Idiopathic Pulmonary Fibrosis Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Idiopathic Pulmonary Fibrosis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Idiopathic Pulmonary Fibrosis Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Idiopathic Pulmonary Fibrosis Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Idiopathic Pulmonary Fibrosis Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Idiopathic Pulmonary Fibrosis Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Idiopathic Pulmonary Fibrosis Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Idiopathic Pulmonary Fibrosis Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<br \/><\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-epidemiology-forecast\">Idiopathic Pulmonary Fibrosis Epidemiology Forecast<br \/><\/a><\/strong>DelveInsight&#8217;s Idiopathic Pulmonary Fibrosis &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Idiopathic Pulmonary Fibrosis.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-pipeline-insight\">Idiopathic Pulmonary Fibrosis Pipeline Insights<br \/><\/a><\/strong>Idiopathic Pulmonary Fibrosis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects in the Idiopathic Pulmonary Fibrosis market.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;About DelveInsight<\/strong><br \/><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=idiopathic-pulmonary-fibrosis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd. 2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=idiopathic-pulmonary-fibrosis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_528080.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-528080","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/528080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=528080"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/528080\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=528080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=528080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=528080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}